Valion Bio To Carry Out Study At Sheba Medical Center To Mull Entolimod In 10 Cancer Participants

Valion Bio, Inc. (NASDAQ:VBIO) today announced a major clinical development milestone with the finalization of an clinical trial protocol at Sheba Medical Center, one of the world's leading hospitals, to evaluate Entolimod in cancer patients receiving high doses of irradiation for a rare form of cancer.

The study, which will enroll up to 10 adult patients, will be conducted by Sheba Medical Center, which approached Valion Bio after recognizing Entolimod's potential to reduce radiation-induced neutropenia and protect healthy tissue during radiation therapy. Under the collaboration, Sheba is planning to fund and conduct the clinical trial, while Valion Bio will provide the investigational drug and support only limited study-related activities outside the standard of care, creating a potential highly capital-efficient opportunity to generate independent clinical data.